BioNTech SE - ADR vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? BioNTech SE - ADR trades at $89.87 (market cap $22.86B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.23. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SPUS | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $59.51 |
52-Week Low | $83.89 | $45.13 |
Enterprise Value | $6.53B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SPUS trades at $57.00, down 1.35% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock is near key support at $57. Recent dividends of $0.03 per share were declared for April, May, and June 2026, reflecting income distribution. News highlights institutional buying and the strength of dividend strategies in U.S. markets.
Outlook remains supported by dividend focus and institutional interest, but limited fundamental data and reliance on broader market trends pose risks. Investors should weigh income benefits against exposure to equity market volatility and economic cycles.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →